Although no patients discontinued ICS treatment, there was a reduction of 28.2% in ICS dosage, observed in only 50% ( n = 3) of the cohort studied, which did not reach statistical significance.
← all excerpts
Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.
1
—
—